The Need
The pharmaceutical industry is facing an R&D productivity crisis, where a $1.4B sunk cost for a Phase III failure is an existential threat. The primary driver of failure is the 'Translational Chasm'—the inability to connect lab-side omics data to clinic-side patient outcomes.
Use Case
The ADC Rescue Mission
Following a $40B acquisition of an Antibody-Drug Conjugate (ADC) asset, a pharmaceutical company finds legacy genomics, clinical results, and digital pathology scans locked in incompatible silos. They leverage the Next-Gen Therapeutics Accelerator for enterprise-grade data ingestion, harmonization, cohorting, and AI tooling.
Through this unified translational factory, the team identifies a novel biomarker signature that predicts treatment responders with 30% greater accuracy, validating the acquisition to the Board.
Our Solution
The Next-Gen Therapeutics Accelerator industrializes your translational workflows, turning bespoke analysis into a repeatable factory. This bundle leverages:
- The Cohort Browser: A unified interface to explore multimodal data. Stratify patients by combining clinical phenotypes with molecular biomarkers to define precise trial cohorts.
- An Automated Ingestion Layer: Standardized ingestion workflows that harmonize data from disparate vendors and assays into a consistent format, eliminating manual cleaning.
- Asset-Ready Data Rooms: Secure, governed workspaces designed for external collaboration. Safely ingest partner data (CROs, academic partners) without uncontrolled file transfers.
- AI/ML Accelerator: Advanced tooling for biomarker discovery, enabling teams to build rigorous ranking models for target identification 2x faster.
- GxP + Omics Data Catalog (ODC): A pre-validated environment to cut FDA/EMA submission preparation time by 6 months.
.png?width=387&height=387&name=ODA%20Brief%20Mockup%20(4).png)
Interested in learning more about The Next-Gen Therapeutics Accelerator?
Your Key Benefits and Outcomes
- Reproducible Science: Move from ad hoc, 'one-off' analyses to consistent, versioned pipelines.
- Faster Collaboration: Spin up secure data rooms for partners in days, not months.
- Unified Stratification: Define complex patient cohorts once and reuse the logic across multiple trial phases.
